# Comparability by design: a digital twin and sentinel panel for cell process changes

Source: https://onco.cc/ideas/idea-reg-comparability-by-design-digital-twin/  
OnCo record `idea-reg-comparability-by-design-digital-twin` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Improving how a cell therapy is made currently risks having to repeat clinical trials. A validated computer model plus a fixed set of product measurements would let changes be approved on data alone.

## Summary

Because assays of how well a cell-therapy batch kills its target are imperfect, regulators often require clinical bridging when a cell-therapy process changes (new device, new site, shorter culture), freezing suboptimal processes. The proposal is a pre-agreed comparability framework: a mechanistic and statistical model of the process (a digital twin) validated against historical runs, a sentinel panel of product attributes (phenotype, transcriptomic signature, cytotoxicity, cytokine profile, vector copy number) with pre-specified equivalence margins, and a regulatory commitment to accept changes that fall within the margins without clinical data.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Under the framework, the median time to implement a major cell-therapy process change falls from more than two years to under six months, with no detectable change in clinical outcomes in the outcomes registry.
- Rationale: Biosimilars established that analytical similarity within margins can replace clinical trials; cell therapies need richer attribute panels, but single-cell and transcriptomic characterisation now make such panels feasible.
- Proposed test: Retrospectively apply the sentinel panel to products that underwent process changes with known clinical outcomes to calibrate margins; then pilot the framework prospectively with two manufacturers and regulators.
- Maturity: speculative
- Actor: regulator

## Sources

- Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018): https://doi.org/10.1001/jamaoncol.2018.0977

## Connected records

- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [Single-cell & spatial profiling](https://onco.cc/technologies/single-cell-spatial/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/), [Regulatory divergence between regions](https://onco.cc/bottlenecks/b-regulatory-fragmentation/)
- key papers: [Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy](https://onco.cc/key-papers/paper-hernandez-jama-oncol/)

---
JSON: https://onco.cc/api/v1/entities/idea-reg-comparability-by-design-digital-twin.json